Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to traumatic choroidal rupture.
Chanana
B
B
Azad
R V
RV
Kumar
N
N
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002829:Choroid / Q000293:injuries*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D006259:Craniocerebral Trauma / Q000150:complications*; D005260:Female; D016489:Head Injuries, Closed / Q000150:complications*; D006801:Humans; D058449:Intravitreal Injections; D016896:Treatment Outcome; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab